60 Jubilee Avenue
Milton Park
Abingdon OX14 4RX
United Kingdom
44 12 3543 0000
https://www.adaptimmune.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 449
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Adrian G. Rawcliffe | CEO, Principal Accounting Officer & Director | 1,06M | 199,16k | 1972 |
Dr. Karen Chagin M.D. | Senior Vice President of Early-Stage Development | S.O. | S.O. | S.O. |
Ms. Margaret Henry | Corporate Secretary | S.O. | S.O. | S.O. |
Ms. Kimberly Freeman | Vice President of Commercial Planning | S.O. | S.O. | S.O. |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
L’ISS Governance QualityScore de Adaptimmune Therapeutics plc en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..